MicroRNA‑192 inhibits cell proliferation and induces apoptosis in human breast cancer by targeting caveolin 1

Chen,Pinjia; Feng,Yun; Zhang,Haige; Shi,Xinpeng; Li,Bin; Ju,Wencui; Yu,Xiurong; Zhang,Nan; Luo,Xiaoyong

doi:10.3892/or.2019.7298

MicroRNA‑192 inhibits cell proliferation and induces apoptosis in human breast cancer by targeting caveolin 1

Authors:
- Pinjia Chen
- Yun Feng
- Haige Zhang
- Xinpeng Shi
- Bin Li
- Wencui Ju
- Xiurong Yu
- Nan Zhang
- Xiaoyong Luo
View Affiliations

Affiliations: Department of Oncology, The Affiliated Luoyang Central Hospital of Zhengzhou University, Luoyang, Henan 471000, P.R. China, Surgical Department, The Affiliated Luoyang Central Hospital of Zhengzhou University, Luoyang, Henan 471000, P.R. China
Published online on: August 30, 2019 https://doi.org/10.3892/or.2019.7298
Pages: 1667-1676
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

It has been demonstrated that microRNA‑192 (miR‑192) serves important roles in different cancer types, including breast cancer, prostate cancer and colorectal cancer. However, its biological role and function in breast cancer remains largely unknown. The present study aimed to determine the role of miR‑192 in breast cancer. In the present study, one normal breast and two breast tumor cells lines were used, which included the normal mammary fibroblast cell line Hs578Bst, a more aggressive breast tumor cell line MDA‑MB‑231 and a less aggressive breast tumor cell line MCF‑7. The effect of miR‑192 on proliferation of breast cancer cells was detected with an MTT assay. Western blot analysis was performed to determine protein expression of caveolin 1 (CAV1). A lentiviral vector that overexpresses pre‑miR‑192 and control lentiviral packaging plasmids were used in the present study. The Student's t‑test was performed to analyze the significance of differences between samples. In the present study, it was determined that the expression of miR‑192 is downregulated in breast cancer, compared with the adjacent normal tissues. Overexpression of miR‑192 significantly inhibited cell proliferation, and induced cell apoptosis and cell cycle arrest in MCF7 and MDA‑MB‑231 cells. Using a bioinformatics method, CAV1 was considered a potential target of miR‑192. Furthermore, it was demonstrated that CAV1 is a direct target of miR‑192 and its protein expression is negatively regulated by miR‑192. Therefore, the present study demonstrated that miR‑192 serves an important role as a regulator in breast cancer and the miR‑192/CAV1 axis has a potential as a therapeutic target for treatment of breast cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Youlden DR, Cramb SM, Dunn NA, Muller JM, Pyke CM and Baade PD: The descriptive epidemiology of female breast cancer: An international comparison of screening, incidence, survival and mortality. Cancer Epidemiol. 36:237–248. 2012. View Article : Google Scholar : PubMed/NCBI
3	Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012. View Article : Google Scholar : PubMed/NCBI
4	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
5	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
6	Ruvkun G: Clarifications on miRNA and cancer. Science. 311:36–37. 2006. View Article : Google Scholar : PubMed/NCBI
7	Xi Y, Shalgi R, Fodstad O, Pilpel Y and Ju J: Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clin Cancer Res. 12:2014–2024. 2006. View Article : Google Scholar : PubMed/NCBI
8	Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
9	Kurozumi S, Yamaguchi Y, Kurosumi M, Ohira M, Matsumoto H and Horiguchi J: Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. J Hum Genet. 62:15–24. 2017. View Article : Google Scholar : PubMed/NCBI
10	Kayani M, Kayani MA, Malik FA and Faryal R: Role of miRNAs in breast cancer. Asian Pac J Cancer Prev. 12:3175–3180. 2011.PubMed/NCBI
11	Mulrane L, McGee SF, Gallagher WM and O'Connor DP: miRNA dysregulation in breast cancer. Cancer Res. 73:6554–6562. 2013. View Article : Google Scholar : PubMed/NCBI
12	Serpico D, Molino L and Di Cosimo S: microRNAs in breast cancer development and treatment. Cancer Treat Rev. 40:595–604. 2014. View Article : Google Scholar : PubMed/NCBI
13	Takahashi Ru, Miyazaki H and Ochiya T: The roles of microRNAs in breast cancer. Cancers (Basel). 7:598–616. 2015. View Article : Google Scholar : PubMed/NCBI
14	Lim LP, Lim LP, Glasner ME, Yekta S, Burge CB and Bartel DP: Vertebrate microRNA genes. Science. 299:15402003. View Article : Google Scholar : PubMed/NCBI
15	Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM Jr, Hofmainster C, Alder H, et al: Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell. 18:367–381. 2010. View Article : Google Scholar : PubMed/NCBI
16	Schotte D, De Menezes RX, Akbari Moqadam F, Khankahdani LM, Lange-Turenhout E, Chen C, Pieters R and Den Boer ML: MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica. 96:703–711. 2011. View Article : Google Scholar : PubMed/NCBI
17	Feinberg-Gorenshtein G, Guedj A, Shichrur K, Jeison M, Luria D, Kodman Y, Ash S, Feinmesser M, Edry L, Shomron N, et al: MiR-192 directly binds and regulates Dicer1 expression in neuroblastoma. PLoS One. 8:e787132013. View Article : Google Scholar : PubMed/NCBI
18	Song B, Wang Y, Kudo K, Gavin EJ, Xi Y and Ju J: miR-192 Regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. Clin Cancer Res. 14:8080–8068. 2008. View Article : Google Scholar : PubMed/NCBI
19	Tan Y, Ge G, Pan T, Wen D, Chen L, Yu X, Zhou X and Gan J: A serum microRNA panel as potential biomarkers for hepatocellular carcinoma related with hepatitis B virus. PLoS One. 9:e1079862014. View Article : Google Scholar : PubMed/NCBI
20	Jin Z, Selaru FM, Cheng Y, Kan T, Agarwal R, Mori Y, Olaru AV, Yang J, David S, Hamilton JP, et al: MicroRNA-192 and-215 are upregulated in human gastric cancer in vivo and suppress ALCAM expression in vitro. Oncogene. 30:1577–1585. 2011. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Augello C, Vaira V, Caruso L, Destro A, Maggioni M, Park YN, Montorsi M, Santambrogio R, Roncalli M and Bosari S: MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver Int. 32:772–782. 2012. View Article : Google Scholar : PubMed/NCBI
23	Goto Y, Kojima S, Nishikawa R, Enokida H, Chiyomaru T, Kinoshita T, Nakagawa M, Naya Y, Ichikawa T and Seki N: The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer. Oncotarget. 5:7748–7759. 2014. View Article : Google Scholar : PubMed/NCBI
24	Jin Y, Lu J, Wen J, Shen Y and Wen X: Regulation of growth of human bladder cancer by miR-192. Tumor Biol. 36:3791–3797. 2015. View Article : Google Scholar
25	Xu YJ and Fan Y: MiR-215/192 participates in gastric cancer progression. Clin Transl Oncol. 17:34–40. 2015. View Article : Google Scholar : PubMed/NCBI
26	Sun J, Fan Z, Lu S, Yang J, Hao T and Huo Q: MiR-192 suppresses the tumorigenicity of prostate cancer cells by targeting and inhibiting nin one binding protein. Int J Mol Med. 37:485–492. 2016. View Article : Google Scholar : PubMed/NCBI
27	Feng S, Cong S, Zhang X, Bao X, Wang W, Li H, Wang Z, Wang G, Xu J, Du B, et al: MicroRNA-192 targeting retinoblastoma 1 inhibits cell proliferation and induces cell apoptosis in lung cancer cells. Nucleic Acids Res. 39:6669–6678. 2011. View Article : Google Scholar : PubMed/NCBI
28	Gupta R, Toufaily C and Annabi B: Caveolin and cavin family members: Dual roles in cancer. Biochimie. 107:188–202. 2014. View Article : Google Scholar : PubMed/NCBI
29	Burgermeister E, Liscovitch M, Röcken C, Schmid RM and Ebert MP: Caveats of caveolin-1 in cancer progression. Cancer Lett. 268:187–201. 2008. View Article : Google Scholar : PubMed/NCBI
30	Wang Z, Wang N, Liu P, Peng F, Tang H, Chen Q, Xu R, Dai Y, Lin Y, Xie X, et al: Caveolin-1, a stress-related oncotarget, in drug resistance. Oncotarget. 6:37135–37150. 2015.PubMed/NCBI
31	Patani N, Martin LA, Reis-Filho JS and Dowsett M: The role of caveolin-1 in human breast cancer. Breast Cancer Res Treat. 131:1–15. 2012. View Article : Google Scholar : PubMed/NCBI
32	Savage K, Lambros MB, Robertson D, Jones RL, Jones C, Mackay A, James M, Hornick JL, Pereira EM, Milanezi F, et al: Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: A morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res. 13:90–101. 2007. View Article : Google Scholar : PubMed/NCBI
33	Yang SF, Yang JY, Huang CH, Wang SN, Lu CP, Tsai CJ, Chai CY and Yeh YT: Increased caveolin-1 expression associated with prolonged overall survival rate in hepatocellular carcinoma. Pathology. 42:438–445. 2010. View Article : Google Scholar : PubMed/NCBI
34	Chatterjee M, Ben-Josef E, Thomas DG, Morgan MA, Zalupski MM, Khan G, Andrew Robinson C, Griffith KA, Chen CS, Ludwig T, et al: Caveolin-1 is associated with tumor progression and confers a multi-modality resistance phenotype in pancreatic cancer. Sci Rep. 5:108672015. View Article : Google Scholar : PubMed/NCBI